Table 3 Prevalence of pfmdr1 polymorphisms in pre-treatment and post-treatment samples stratified by study site
pfmdr1a | Pre-treatment (N = 109) | Post-treatment (N = 48) | ||||||
|---|---|---|---|---|---|---|---|---|
MEGA | MEZE | MEMP | MEIA | MEGA | MEZE | MEMP | MEIA | |
n = 39 | n = 12 | n = 20 | n = 38 | n = 22 | n = 1 | n = 3 | n = 22 | |
Y184 | 10 (25.6) | 4 (33.3) | 9 (45.0) | 19 (50.0) | 6 (27.3) | 0 (0) | 0 (0) | 6 (27.3) |
184Y/F | 8 (20.5) | 3 (25.0) | 6 (30.0) | 7 (18.4) | 8 (36.4) | 1 (100) | 0 (0) | 8 (36.4) |
184F | 21 (53.8) | 5 (41.7) | 5 (25.0) | 12 (31.6) | 8 (36.4) | 0 (0) | 3 (100) | 8 (36.4) |
NYD | 18 (46.2) | 7 (58.3) | 15 (75.0) | 26 (68.4) | 14 (63.6) | 1 (100) | 0 (0) | 14 (63.6) |
NFD | 29 (74.4) | 8 (66.7) | 11 (55.0) | 19 (50.0) | 16 (72.7) | 1 (100) | 3 (100) | 16 (72.7) |